⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 1, 2023MedOpen Access

Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

This work was funded by Oncode PoC 2018-P0003.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Millen et al. (2023) studied this question.

synapsesocial.com/papers/69de7d8fda08968cf7b0c4d4 https://doi.org/10.1016/j.medj.2023.04.003

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

1MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 AxisOriginal Research · 2016 · 428 citations
2Patient-derived organoids model treatment response of metastatic gastrointestinal cancersEarly-Phase Clinical Trial · 2018 · 2,186 citations
3Targeted therapy for head and neck cancer: signaling pathways and clinical studiesReview · 2023 · 229 citations
4Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical TrialsHuman Clinical Trial · 2014 · 503 citations